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Objectives: To assess the performance of a 5-type
human papillomavirus (HPV) messenger RNA (mRNA)
test in primary screening within the framework of the
Norwegian population-based screening programme.
Design: Nationwide register-based cohort study.
Setting: In 2003–2004, general practitioners and
gynaecologists recruited 18 852 women for
participation in a primary screening study with a 5-type
HPV mRNA test.
Participants: After excluding women with a history of
abnormal smears and with cervical intraepithelial
neoplasia grade 2 (CIN2+) before or until 3 months after
screening, 11 220 women aged 25–69 years were
eligible for study participation. The Norwegian Cancer
Registry completed follow-up of CIN2+ through 31
December 2009.
Interventions: Follow-up according to the algorithm for
cytology outcomes in the population-based Norwegian
Cervical Cancer Screening Programme.
Main outcome measures:We estimated cumulative
incidence of CIN grade 3 or worse (CIN3+) 72 months
after the 5-type HPV mRNA test.
Results: 3.6% of the women were HPV mRNA-positive
at baseline. The overall cumulative rate of CIN3+ was
1.3% (95% CI 1.1% to 1.5%) through 72 months of
follow-up, 2.3% for women aged 25–33 years (n=3277)
and 0.9% for women aged 34–69 years (n=7943).
Cumulative CIN3+ rates by baseline status for HPV
mRNA-positive and mRNA-negative women aged
25–33 years were 22.2% (95% CI 14.5% to 29.8%) and
0.9% (95% CI 0.4% to 1.4%), respectively, and 16.6%
(95% CI 10.7% to 22.5%) and 0.5% (95% CI 0.4% to
0.7%), respectively, in women aged 34–69 years.
Conclusions: The present cumulative incidence of
CIN3+ is similar to rates reported in screening studies via
HPV DNA tests. Owing to differences in biological
rationale and test characteristics, there is a trade-off
between sensitivity and specificity that must be balanced
when decisions on HPV tests in primary screening are
taken. HPV mRNA testing may be used as primary
screening for women aged 25–33 years and 34–69 years.
INTRODUCTION
Cervical cancer is the fourth most common
cancer among women worldwide.1 Cervical
human papillomavirus (HPV) infection is
necessary but not sufficient to cause cervical
cancer.2 3 HPV is one of the most common
sexually transmitted infections with a preva-
lence ranging from 20% to 30% in women
aged 16–29 years.4 5 The lifetime risk of HPV
infection in women is 70–80%.3
Approximately 15 HPV genotypes, referred
to as high-risk (HR) types, are considered
aetiological agents of cervical cancer.6 HPV16
is by far the most significant HPV type in per-
sisting infection and promoting progression
into high-grade cervical intraepithelial neo-
plasia or worse (CIN3+).7 8 Given the strong
aetiological association between HR HPV
infection and cervical cancer, HR HPV testing
is considered an alternative for cytology-based
cervical cancer screening.9
A review of seven randomised controlled
trials (RCT) concluded that HPV testing in
combination with cytology detected 67%
more CIN3+ lesions in the first screening
round compared with cytology-based screen-
ing alone for women aged 29 years and older
(95% CI 1.27 to 2.19).10 In the second
screening round, fewer CIN3+ lesions were
detected in the HPV arm than in the
cytology arm (risk ratio 0.49 (95% CI 0.37 to
Strengths and limitations of this study
▪ We consider studying primary screening with a
5-type human papillomavirus (HPV) messenger
RNA (mRNA) test in a population of women with
no previous cervical intraepithelial neoplasia
grade 2 and/or abnormal smears as a strength
as the HPV infections diagnosed are likely to be
‘new’ infections.
▪ We consider the follow-up within the Norwegian
Cervical Cancer Screening Programme as
strength, as women regardless of mobility within
Norway, are captures by the surveillance system
for cytology, histology and treatment.
▪ We consider just having one screening round
with the 5-type HPV mRNA test as a limitation,
in addition to follow-up based on cytology only
(verification bias).
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0.66)). The cumulative CIN3+ detection rates over two
screening rounds were not different (risk ratio 1.09
(95% CI 0.84 to 1.42)).10
The specificity of HPV DNA tests for CIN3+ is low, and
the positive predictive value is low in groups with low
CIN3+ incidence (eg, particularly young, sexually active
women). The real cause of cervical cancer is not the HPV
infection per se, but the continuous overexpression of
the viral oncogenes E6 and E7 from oncogenic HPV
types.11 There may be several reasons why E6 and E7 are
overexpressed, but one of the main reasons is virus’s inte-
gration into the human genome (loss of E2 gene results
in loss of transcript regulation). The loss of the E2 gene
only occurs in a small proportion of women with HPV
infection.12 This implies that a test that detects the over-
expression of E6 and E7 messenger RNA (mRNA) is
more specific than a test that detects the presence of viral
DNA. Not all cervical cancers have integrated viral forms;
between 15% and 20% will have episomal forms only.
Integration is not a requisite for transformation.13
HPV E6/E7 mRNA is a rational target for detecting
HPV infections leading to cellular transformation. The
HPV mRNA test PreTect HPV-Proofer detects E6/E7
mRNA of the five main HR HPV types, namely 16, 18,
31, 33 and 45, which are associated with 86% of cervical
cancers in Europe.14 15 Owing to the higher specificity
for CIN2+ of PreTect HPV-Proofer compared to other
HPV tests,16–22 this test may have favourable character-
istics in screening for cervical precancers. The aim of
this study was to evaluate the performance of an HPV
mRNA test in primary cervical cancer screening.
MATERIAL AND METHODS
The study comprised 18 852 women aged 13–87 years
visiting gynaecologists and general practitioners in differ-
ent parts of Norway between 1 May 2003 and 31
December 2004. Women were included after an individ-
ual assessment by their physician.
The departments of pathology and microbiology,
University Hospital of Northern Norway, Tromsø, orga-
nised the study. Within the study’s legal framework, par-
ticipant identification from the unique 11-digit personal
identification number, kept by all Norwegian citizens,
was merged with lifetime data on cervical cytology and
histology in four national registries administered by the
Norwegian Cancer Registry (NCR). With these mergers,
a complete follow-up through 31 December 2009 was
possible. A mandatory reporting on cancer to NCR has
been practised since 1953, on cervical cytology since
1995 (1992) and on cervical histology since 2002 from
all cytology/pathology laboratories. In addition, since
1997, gynaecology departments and practitioners collect-
ing cervical biopsies/carrying out CIN treatment have
been encouraged to report individual case report forms
to NCR on CIN treatment.
In the merged data set, we excluded women with an
abnormal smear history (n=4535) or a histology history
of CIN2+ (n=871) prior to or until completion of
3 months (119 days) after the date of screening. In add-
ition, we excluded women aged <25 years (n=2012) or
>69 years (n=214). A total of 11 220 women aged 25–69
years in a situation resembling primary screening (table 1)
were eligible.
Conventional pap tests and liquid-based cytology
(LBC) were analysed in local cytology laboratories. In
cases with conventional pap tests, extra specimen collec-
tions (PreTect TM) were made for HPV analysis. We
extracted cervical cells from LBC by the ThinPrep 2000
(Cytyc Corporation, Marlborough, Massachusetts, USA)
for cytological examination. DNA/RNA was isolated
from 5 mL of the leftover material of the LBC (or from
the PreTect TM). All women were subjected to detection
of HPV mRNA (PreTect HPV-Proofer, PreTect AS,
Klokkarstua, Norway) in one laboratory. The HPV
laboratory worked independently of the cytology depart-
ments, being unaware of the cytology results at the time
of HPV detection and vice versa.
Biopsies were evaluated by pathologists and histo-
logical results were reported using CIN terminology.23
Pathology laboratories in Norway use the same classifica-
tion system for cytology (Bethesda) and histology (CIN).
Every year, all the laboratories receive reports from the
NCR on laboratory-specific diagnostic performance.
Annual meetings are held so cytologists and pathologist
secure consistent classifications of diagnosis in cervical
cancer prevention.
The national screening programme in Norway recom-
mends all women aged 25–69 years to have cervical
cytology (pap test) every third year. A national quality
manual for cervical cancer prevention is continuously
updated (http://www.kreftregisteret.no). Women with
normal cytology are encouraged to do another screen
within 3 years. Women with high-grade cytology (atypical
squamous cells—cannot exclude highgrade squamous
intraepithelial lesion (HSIL) (ASC-H/HSIL)) are referred
immediately to colposcopy and biopsy. Prior to 2005,
women with equivocal or low-grade cytology (atypi-
cal squamous cells of undetermined significance
Table 1 Selection of study population
N N
Eligible 18 852
History of ASC-US/LSIL 3218
History of HSIL 1317
History of CIN1+ 716
Age <25 years 2012
Age ≥70 years 214
CIN1+ at study start 128
CIN1+ <120 days after study start 27
In total 7632
Study population 11 220
ASC-US, atypical squamous cells of undetermined significance;
CIN1, cervical intraepithelial neoplasia grade 1; LSIL, low-grade
squamous intraepithelial lesion.
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(ASC-US/low-grade squamous intraepithelial lesion
LSIL)) were triaged by repeat cytology after 6 months.
Women with repeated equivocal or low-grade cytology
(ASC-US/LSIL×2) were triaged by repeat cytology after
an additional 12 months. Women with persistent equivo-
cal or low-grade cytology (ASC-US/LSIL×3) over a
period of 18 months were referred to colposcopy and
biopsy. Delayed HPV triage was implemented in the
national screening programme in 2005. Women with
ASC-US/LSIL were recommended repeat cytology and
HPV testing after 6–12 months. Women with a positive
HPV test and abnormal cytology were referred to colpos-
copy and biopsy. Women with a positive HPV test and
normal cytology were retested after 12 months for per-
sistence. Women with two consecutive positive HPV tests
were referred for colposcopy and biopsy (http://www.
kreftregisteret.no). The HPV tests used in Norway
during 2005–2009 were Hybrid Capture II, PreTect
HPV-Proofer and Amplicor.24
In Norway, the threshold for treatment by conization
or large loop excision of the transformation zone
(LLETZ) is CIN2. Outcome assessment was based on
the histological result of biopsies, where CIN2+ was con-
sidered as the target disease and CIN1 and no CIN were
considered as absence of disease. Only cervical cancer
reported in the cancer file (validated by NCR against
pathology reports at hospital) were true cases of cancer.
SPSS V.22 was used to conduct all statistical analyses,
which entailed χ2 tests, Mann-Whitney tests and survival
analyses. A p value <0.05 was considered statistically
significant.
The Regional Committee for Medical Research Ethics,
Region East, Oslo, Norway, reviewed the study. The com-
mittee approved merging the laboratory data on HPV
and cytology/histology data from NCR without informed
consent from the participants (REK Sør-Øst 2010/2858).
RESULTS
At study start, the detection rate of HPV mRNA was
3.6% (n=399) among 11 220 women with no history of
abnormal smears or history of abnormal cervical hist-
ology registered in NCR. Nearly half (189/399=47.4%)
of the HPV-positive women were HPV16 positive. HPV16
was the single infection in 175 of 189 infections (92.3%)
(tables 2 and 3). HPV45 was more prevalent than
HPV18, HPV33 and HPV31. For all HPV types, the infec-
tion prevalence decreased significantly by age (tables 2
and 3) (p<0.001).
The 11 220 women were followed for 767 407 women
months, with a mean of 68.4 months and a range of
4–80 months. During the study period of 80 months,
158 women (1.4%) developed CIN2+. The distribution
of CIN2 relative to CIN3+ cases decreased by age (20%
among women aged 25–33 years, 12% in women aged
34–69 years).




N 3277 7943 11 220
HPV status Per cent Per cent Per cent
HPV-negative 92.9 97.9 96.4
HPV31/33/45
(not 16, not 18)
2.6 0.8 1.4
HPV18 (not 16) 1.0 0.3 0.5
HPV16 3.4 1.0 1.7
Table 3 Cumulative proportion of cervical intraepithelial neoplasia 2+ and CIN3+ at 36 and 72 months by human
papillomavirus status at baseline (95% CIs)
36 months 72 months
CIN2+ CIN2+
HPV status N % 95% CI % 95% CI
In total 11 220 0.78 0.62 to 0.94 1.52 1.27 to 1.77
HPV-negative 10 821 0.28 0.20 to 0.40 0.77 0.58 to 0.96
HPV-positive 399 14.0 10.5 to 17.5 22.7 17.5 to 28.9
HPV31/33/45 (not 16, not 18) 152 9.2 4.6 to 13.8 16.3 8.4 to 24.2
HPV18 (not 16) 58 17.2 7.5 to 26.9 20.7 20.3 to 31.1
HPV16 189 16.9 11.5 to 22.3 27.8 20.5 to 35.1
CIN3+ CIN3+
HPV status N % 95% CI % 95% CI
In total 11 220 0.67 0.51 to 0.83 1.27 1.04 to 1.51
HPV-negative 10 821 0.28 0.20 to 0.40 0.62 0.46 to 0.79
HPV-positive 399 11.3 8.2 to 14.5 19.7 14.7 to 24.7
HPV31/33/45 (not 16, not 18) 152 7.2 3.1 to 11.3 14.3 6.7 to 21.9
HPV18 (not 16) 58 12.1 3.7 to 20.5 17.2 7.5 to 26.9
HPV16 189 14.3 9.3 to 19.3 24.1 17.0 to 31.2
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The cumulative proportions of both CIN2+ (table 3)
and CIN3+ (table 3 and figure 1) were significantly
higher in the younger (25–33 years) than older (34–69
years) women (survival analysis, p<0.001). At 36 and
72 months of follow-up, the cumulative proportions of
CIN3+ were 0.95% (95% CI 0.62% to 1.28%) and 2.32%
(95% CI 1.65% to 2.99%), respectively, for women aged
25–33 years, and 0.55% (95% CI 0.39% to 0.71%) and
0.87% (95% CI 0.65% to 1.09%), respectively, for
women aged 34–69 years. After adjusting for HPV status
at baseline, there were no differences in proportions of
CIN2+ or CIN3+ (figure 2) between HPV-negative and
HPV-positive women aged 25–33 or 34–69 years.
However, HPV-positive women had significantly higher
proportions of both CIN2+ and CIN3+ independent of
age. The slope of the curve for proportions of CIN3+
(figure 2) among the younger HPV-positive women
(25–33 years at baseline) increased linearly after
36 months, while the slope of the curve for proportions
of CIN3+ among older women (34–69 years) levelled off
(insignificant).
The cumulative proportions of CIN2+ and CIN3+ at
36 and 72 months in women who were HPV positive or
HPV-negative at baseline are displayed in table 3. In
total, the cumulative proportions of CIN2+ or CIN3+
were significantly higher in women who were HPV16
positive at baseline compared to women who were
HPV31/33/45 positive at baseline. There were no differ-
ences in CIN2+/CIN3+ between women who were
HPV16 positive and women who were HPV18 positive at
baseline. Owing to the small sample size, the same is the
case between women who were HPV18 positive and
women who were HPV31/33/45 positive at baseline
(table 3). The slope of the curves, as displayed in
figure 2, was similar across age (data not shown), but
was inconsistently significant due to the small numbers.
The cumulative proportions of CIN2+ and CIN3+
among HPV-negative women remained low throughout
the study period (table 3 and figure 2).
All five cases of cervical cancer were diagnosed among
women 40 years or older. One 42-year-old woman with
HPV16 at baseline developed squamous cell carcinoma
after 13 months. Another 42-year-old woman with
HPV18 developed adenocarcinoma after 59 months.
The three other cases were at ages 51, 57 and 59 years at
baseline, were all HPV-negative and were diagnosed
after 65, 22 and 33 months of observation—two adeno-
carcinomas and one squamous cell carcinoma. The
cumulative incidence of cervical cancer was 47.0 (95%
CI 5.8 to 88.2) per 100 000 women months at 72 months
of observation (7.8/100 000 women per year).
DISCUSSION
Our study examines a low-risk population as we excluded
at study start all women with a history of abnormal
cytology and/or histology from cervix uteri. These exclu-
sions removed persistent HPV infections expressing on
and off low-grade lesions over time, thus reducing HPV
positivity. In addition, HPV positivity will be lower with
an mRNA test targeting oncogenic expression, com-
pared with a DNA test that detects HPV presence.
The present HPV mRNA positivity rate of 7.1% in
women aged 25–33 years and 2.1% in women aged 34–69
years is much lower than those reported from studies
using HPV DNA tests. In the Horizon study,25 across all
age groups, 898 of 4413 (20.3%) samples were HPV
DNA-positive (Cobas 4800, Roche Molecular Systems,
Pleasanton, California, USA) with normal cytology.
This proportion decreased from 33.9% in women aged
23–29 years to 18.6% at age 30–39 years and 6.0% at age
50–65 years.25 This implies that HPV DNA primary
screening in women younger than 40 years will lead to
huge administrative challenges in the light of low inci-
dence of cervical cancer. Cytology in triage of women
with a positive HPV DNA test may reduce the burden of
Figure 1 Cumulative incidence of cervical intraepithelial
neoplasia 3 or worse (CIN3+) by age.
Figure 2 Cumulative incidence of cervical intraepithelial
neoplasia 3 or worse (CIN3+) in human papillomavirus-
positive and HPV-negative women by age.
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colposcopy, but triage-negative women still need
follow-up.26 27 A woman with a positive HPV test has an
increased risk of CIN3+ even though cytology is
normal.27 28
The risks of CIN3+ after 36 months of follow-up were
0.67% overall and 0.28% in the HPV mRNA-negatives, a
relative reduction of 58%. The risks of CIN3+ after
72 months of follow-up were 1.27% overall and 0.62% in
the HPV mRNA-negatives, a relative reduction of 51%.
Our results are in line with outcomes for primary screen-
ing with HPV DNA tests.7 29–31 A Danish study using
Hybrid Capture 2, CIN3+ after 72 months of follow-up
reported 2.0% overall and 1.0% in the HPV
DNA-negatives, a relative reduction of 50%.7 In a US
cohort of 20 810 women, HPV-negative/pap-negative
women had a CIN3+ cumulative incidence rate of 0.16%
after 45 months and 0.79% after 122 months.32 Similarly,
in a German cohort of 4034 women, 0.7% of
HPV-negative/pap-negative women developed CIN3+
during 5 years of follow-up.31 In a Dutch cohort of 2810
women, there was only one case of CIN3+ among
women with negative results on both tests during
4.6 years of follow-up.29 In a US cohort of 19 512
women, a one-time negative HR-HPV test at enrolment
provided greater reassurance over the 18-year follow-up
than did a one-time negative pap against CIN2+ (1.85%
vs 2.47%) and CIN3+ (0.90% vs 1.27%). In comparison,
cumulative incidence was 1.73% for CIN2+ and 0.83%
for CIN3+ after one-time HPV and pap tests that were
both negative.30 In our study, the cumulative incidence
of CIN3+ after 6 years was 1.3% for women with negative
cytology and 0.6% for women with double negative
cytology and HPV mRNA test, respectively. Since CIN3+
incidence depends on HPV prevalence, some hetero-
geneity between studies might be explained by differ-
ences in HPV prevalence and age at inclusion.
In a meta-analysis of European HPV primary studies,
the cumulative incidence rate of CIN3+ after 6 years was
considerably lower among women with a negative HPV
at baseline 0.27%(95% CI 0.12% to 0.45%) than among
women with negative results on cytology 0.97%(95% CI
0.53% to 1.34%). In comparison, the cumulative inci-
dence rate for women with negative cytology results at
the most commonly recommended screening interval in
Europe (3 years) was 0.51% (95% CI 0.23% to 0.77%).
The cumulative incidence rate among women with nega-
tive cytology results who were positive for HPV increased
continuously over time, reaching 10% at 6 years, whereas
the rate among women with positive cytology results who
were negative for HPV remained below 3%.33
The HPV mRNA test employed in our study detects
five HPV types (16, 18, 31, 33, and 45) associated with
86% of cervical cancers in Europe.14 15 Women with
other HPV types had a negative HPV mRNA test. Still,
the cumulative risk of CIN3+ 6 years after a negative
HPV mRNA test was low (0.62%). Most HPV DNA tests
detect 13 or 14 HPV types. In a Danish study most of
the HPV-positive CIN3+ cases were of HPV types 16, 18,
31 and 33.7 The cumulative risk of CIN3+ after 6 years
in women with a positive HPV test of other HPV types
was not significantly different from women with a nega-
tive Hybrid Capture 2.7 In Europe, HPV16 predominates
in CIN3 and cervical cancer. Other HPV types have a
slower progression into cancer.34 The risk of cervical
cancer development is higher for HPV types 16, 18, 31,
33 and 45 than for other HPV types.35
It is important to improve the screening in young
women. CIN3 detection from 25 years is important for
decreasing the risk of cervical cancer, even in the post-
vaccinated era.36 In the Addressing THE Need for
Advanced HPV Diagnostics (ATHENA) trial, more CIN3
+ was found in women aged 25–29 years than in all
women aged 40 years and older. Of all CIN3+ found in
the study, 28% occurred among women aged 25–
29 years, versus 25% in women aged 40 years or older.37
Over the past 20 years, Norway has witnessed
an increase in cervical cancer rates in women younger
than 40 years, despite cytology screening (http://www.
kreftregisteret.no). In the USA, corroborating data
from the National Cancer Institute’s Surveillance,
Epidemiology and End Results (SEER) tumor registry
show a sharp rise in the incidence of invasive cervical
cancer between the ages of 25 and 34 years (http://seer.
cancer.gov, table 5.7). In the ATHENA study, 57.3% of
women aged 25–29 years with CIN3+ had a negative
cytology (NILM).37
In 2003/2004, there were no national guidelines for
HPV testing and follow-up of HPV-positive women. Most
CIN3+ cases were detected by passive follow-up in
routine cervical cancer screening based on cytology
every 3 years. This may result in verification bias favour-
ing cytology when women with abnormal cytology were
followed up, but not women with a positive HPV test.
Given that HPV mRNA-negative women retained their
low risk of CIN3+ for at least 6 years, frequent screening
of these women may be unnecessary. New HPV infec-
tions are associated with an extremely low risk of cancer
because they usually resolve without the need for
medical intervention.38
CONCLUSION
HPV mRNA testing may be used as primary screening
for women aged 25–33 years and those aged 34–69
years. Studies designed to do ‘head-to-head’ comparison
between HPV DNA and HPV mRNA tests in primary
screening of CIN3+ are welcome.
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